Germany Archives

Epigenomics cancer colorectal china CFDA beijing biochain diagnostic blood test epiprocolon septin9

News and Trends 4 May 2016

‘First Blood Test for Colorectal Cancer is One of the most Innovative Medical Products’ says Chinese FDA

That’s what the China Food and Drug Administration (CFDA) declared on the blood diagnostic test from Berlin-based Epigenomics‘ proprietary Septin9-Biomarker. Their Septin9 test Epi proColon is filling the need for early detection of colorectal cancer. Data show a huge increase in prevalence in urban China.Just last week we interviewed the CEO of Epigenomics, Thomas Taapken, on the company’s Cancer […]

May 4, 2016 - 3 minutesmins - By Dani Bancroft

bioart biomolecule antibody medicine sculpture protein art julian voss andreae

News and Trends 30 Apr 2016

BioArt : Julian Voss-Andreae Materialises Molecules through Metal Sculpture

Last week we also looked at molecular sculpture, but with the medium of Glass. Now we turn to metal work and the challenges of scaling up molecular design work with the German BioArtist Julian Voss-Andreae. Julian was originally a quantum physicist from Germany who studied in Berlin, Edinburgh and then Vienna before returning to the artist path […]

April 30, 2016 - 4 minutesmins - By Dani Bancroft

morphosys novartis muscle simb bimagrumab

News and Trends 27 Apr 2016

‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease

MorphoSys confirms that its antibody (bimagrumab) failed to meet the primary endpoint of a phase IIb/III trial for a muscle disease (sIBM), conducted by Novartis. Sad news for Novartis and MorphoSys. The two companies are developing bimagrumab for muscle diseases, as part of their ongoing collaboration, which has already resulted in 11 programmes. Bimagrumab was initially […]

April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 21 Apr 2016

New CRISPR Tool can cut RNA too: Gene Editing just got even Easier!

The research team led by Emannuelle Charpentier, co-discoverer of the CRISPR/Cas9 system, has found that a new CRISPR system can also cleave RNA. Amazingly simple! The discovery of the CRISPR/Cas9 system revolutionised Biotechnology, unlocking a kind of ‘Golden age’ for gene editing – with a wide-reaching impact from therapeutics to SynBio. So, it’s no wonder that […]

April 21, 2016 - 3 minutesmins - By Denise Neves Gameiro

aacr 2016 merus transgene debiopharma innate

News and Trends 21 Apr 2016

These EU Biotechs presented groundbreaking results at World Biggest Cancer Meeting

The annual meeting of the American Association for Cancer Research (AACR) has just finished. From Europe, who made a splash with their results? The AACR annual meeting is the world’s biggest conference in Cancer research, and the must-attend event for Biotechs developing cancer therapies. The 2016 edition took place in New Orleans (US) from the […]

April 21, 2016 - 5 minutesmins - By Denise Neves Gameiro

gsk morphosys hand osteoarthritis rheumatoid

News and Trends 19 Apr 2016

GSK goes to phase II with German Antibody for Inflammatory Diseases

GSK has started a phase II trial for inflammatory hand osteoarthritis, with a candidate originally from MorphoSys‘ antibody library. GSK, a big UK Pharma, has announced the start of a phase II study to evaluate the efficacy and safety of its candidate, GSK3196165. The trial will enroll 40 patients with hand osteoarthritis – a condition that damages […]

April 19, 2016 - 2 minutesmins - By Denise Neves Gameiro

oxford biotherapeutics drug cancer boehringer

News and Trends 18 Apr 2016

UK Drug Discovery sells Cancer Target to German Pharma

Boehringer Ingelheim has bought exclusive rights to an oncology target discovered by Oxford BioTherapeutics and its proteomic database. Oxford BioTherapeutics is a Biotech in Milton Park (near Oxford, UK), developing immunotherapies for cancer with antibody-drug conjugates (ADC) – a strategy to combine the specificity of antibodies to a toxic agent that can be delivered to a cancerous cell. […]

April 18, 2016 - 2 minutesmins - By Denise Neves Gameiro

nsclc mirati qiagen cancer oncology lung mrna

News and Trends 15 Apr 2016

Qiagen Deal to make Genetic Diagnostic Test for Lung Cancer

Qiagen and Mirati will collaborate on the development of a companion diagnostic for a specific type of form of Non-Small Lung Cancer – supporting Mirati’s new therapy. With its operational headquarters near Düsseldorf (Germany), Qiagen is an EU giant in Molecular Diagnostics, and even stepped into the NGS battleground after the acquisition of an important supplier. Qiagen is now entering […]

April 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

labiotech thomas taapken epicolon biotech epigenomics cancer philipp hemme berlin

News and Trends 14 Apr 2016

We met the Biotech with the First & Only US Approved Blood Test for Colorectal Cancer

Colorectal cancer is the second biggest cancer killer in the US, but Epigenomics could dramatically improve this sad figure. A problem Berlin-based Epigenomics want to solve and just got a significant milestone: an FDA approval for commercialisation. I met with Thomas Taapken, the CEO of the company, in his office in Berlin, a nice historical building with 4 meters ceiling […]

April 14, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 13 Apr 2016

Leading Biotech VC in Europe Raises over €180M

Forbion has raised €183M for its 3rd capital fund – a big win for this top-notch Dutch VC, especially when stock markets are getting ever less friendly. Forbion is one of the best European VCs in Europe for Biotech. Based primarily near Amsterdam (it also has offices in Munich), it is probably a factor in […]

April 13, 2016 - 2 minutesmins - By Denise Neves Gameiro

morphosys galapagos inflammatory mor106 mab

News and Trends 7 Apr 2016

Two of the Biggest European Biotechs launch Antibody Program together

MorphoSys (Germany) and Galapagos (Belgium) have announced a new joint program to conduct a phase I trial for a first-in-class antibody, MOR106, that could be used to treat inflammatory diseases. Just after announcing that it is suing Janssen Biotech and Genmab (Denmark), Munich-based MorphoSys is still keeping things interesting – this time with a phase I trial for […]

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

affimed afmd 2015 results immuno oncology

News and Trends 31 Mar 2016

The ‘Formative Year’ of Germany’s only NASDAQ-listed Biotech

Affimed from Heidelberg had a ‘formative year’ (hmm) in 2015. Major highlights include raising of €52.6M, expanding to the US and advances in the development of its next-generation antibodies for immuno-oncology. Affimed is a Biopharma focused on discovering and developing highly targeted cancer immunotherapies. It is also one of our trendiest NASDAQ-listed European Biotechs (and the only one […]

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Germany

‘First Blood Test for Colorectal Cancer is One of the most Innovative Medical Products’ says Chinese FDA

BioArt : Julian Voss-Andreae Materialises Molecules through Metal Sculpture

‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease

New CRISPR Tool can cut RNA too: Gene Editing just got even Easier!

These EU Biotechs presented groundbreaking results at World Biggest Cancer Meeting

GSK goes to phase II with German Antibody for Inflammatory Diseases

UK Drug Discovery sells Cancer Target to German Pharma

Qiagen Deal to make Genetic Diagnostic Test for Lung Cancer

We met the Biotech with the First & Only US Approved Blood Test for Colorectal Cancer

Leading Biotech VC in Europe Raises over €180M

Two of the Biggest European Biotechs launch Antibody Program together

The ‘Formative Year’ of Germany’s only NASDAQ-listed Biotech

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!